Menuda sangria
Hola
Estoy viendo que la rentabilidad por dividendo es como del 12% ¿Lo veis sostenible?
Un saludo
A precios actuales casi el 10% de RPD. Lo acaban de recortar, pero no sería la primera empresa que hace un recorte sobre el recortado…
2 Me gusta
JPMorgan Cazenove upgraded its rating on shares of Imperial Brands on Friday to ‘overweight‘ from ‘neutral’
As it said the current valuation is pricing in severe downside risks, leaving the risk/reward tilted strongly to the upside following the dividend cut in May. “Supported by its robust free cash flow…we see IMB’s circa 50% payout ratio as sustainable with a further £1bn+ per annum available for cash returns or M&A from FY23e in our base case,” said JPM.
The bank also said that with IMB’s valuation discounting its “listless direction”, the arrival of new external chief executive Stefan Bomhard provides free optionality should he show competency and his new perspective can begin to re-build investor confidence. JPM cut its price target on Imperial Brands to 1,650p from 1,700p.
Con unos 940 millones de acciones en circulacion ese billon de libras extra disponible da para algo mas de 1 libra de dividendo extra por accion ¿entonces para que lo recortas con el coste de la deuda en minimos historicos? ¿solo por joder y terminar de hundir la cotizacion?
7 Me gusta
Los insiders se habrán hinchado a comprar…
7 Me gusta
Imperial Brands released reasonably strong full year results for fiscal 2020. Both volume and margins were ahead of our expectations. We continue to regard Imperial as being materially undervalued, and although this stable trading performance and guidance of modest profit growth next year is good news, we think it will take the communication of clear strategies to increase price/mix in the cigarettes portfolio and to gain share in next generation products for the upside to the market value to be realised. We retain our GBX 3,400 fair value estimate.
New CEO Stefan Bomhard is off to a good start. Adjusted full year revenue grew 0.8% over the prior year, with a 2% tobacco volume decline more than offset by pricing. The volume data was slightly better than our forecast, and implies market share gains, but this was driven by the value end of the portfolio, meaning there was modest pressure on the gross margin, which remained flat over last year. COVID-19 is likely to have played a role in supporting volumes of discount cigarettes, and we suspect mix will continue to be unfavourable in the first half of the next fiscal year as well. Nevertheless, the 20 basis point decline in operating profit was less than we had feared, in part because the decline in revenue from next generation products of around 30% was less than we had feared.
Imperial Brands backed the wrong horse when it invested heavily in vaping, a category that always seemed likely to fall foul of regulators by appealing to new consumers, and stayed on the sidelines while Philip Morris International succeeded in winning share in heated tobacco. A new strategy is required to persuade investors that Imperial will not stand by and watch its decline rate accelerate as smokers migrate to substitute products. The news that the market testing of Pulze had not gone well is disappointing, and suggests that incremental R&D spending will be required for Imperial to win share in the next generation product market.
13 Me gusta
Buenas, me ha saltado alerta en Clicktrader para dividend reinvested de IMB. Tenemos hasta el 9 de Diciembre para hacer la elección.
¿Alguien sabe cuantas acciones hay que tener para que te den otra adicional?..no logro verlo en ningún sitio.
Gracias por adelantado, un saludo
No es un scrip dividend, es un DRIP
3 Me gusta
Ok, gracias ruindog…si me acojo al DRIP ¿Qué ocurre con los restos que no cubran acciones completas?..supongo que me darán cash.
Quiero hacer la elección como en el caso de SCRIP (como hago con IBE), eligiendo exactamente el número de acciones por partes enteras y el resto en cash. Supongo que eso no lo sabré hasta el día 9 de Diciembre,¿no?
Gracias por la ayuda, en temas de DRIP Y SCRIP sigo muy verde 
Aquí no hay cotización de derechos ni nada parecido. Tu solo les das orden al broker para que reinvierta el dividendo de IMB.
Si recibes 151€ de dividendo neto y al reinvertirse en la compra de nuevas acciones de la misma compañía estas cotizan a 15€ al final acabarás con 10 acciones y 1 euro más en tu cuenta de valores.
3 Me gusta
Creo que con los DRIP no es igual que con los Scrip, ya que lo que hacen es comprar con el dividendo que te corresponde la acciones nuevas que se pueda, lo único que no se sabe que día lo hacen y que precio se paga. Lo bueno es que se ahorra uno muchas comisiones, pero luego ese cobro hay que declararlo , es decir en la proxima declaración hay que pagar el 19%. No es como con el Scrip que hasta que no vendas no pagas nada.
Yo siempre cojo efectivo, para no tener más lio con la declaración.
Un saludo
5 Me gusta
Gracias Felpeyu y ruindog, ya me voy aclarando.
1 me gusta
1 me gusta
La JUUL china sale a bolsa y ya vale mas que Imperial Brands 
El otro día estaba leyendo un artículo sobre la IPO y coincide con la visión de este caballero. Su mayor problema y competidor es precisamente el gobierno chino
RLX is seeking U.S. public capital market investment for its expansion plans within China.
The company’s financials show strong topline revenue growth, slight earnings and significant cash flow from operations and free cash flow.
Selling expenses as a percentage of total revenue have dropped as revenues have increased and its Selling efficiency ratio has improved. Both signals are positive as to the firm’s capital efficiency in this important area.
The market opportunity for selling e-cigarettes in China is approximately 290 million smokers and management says this is the largest single such market in the world.
Citigroup is the lead left underwriter and IPOs led by the firm over the last 12-month period have generated an average return of 31.7% since their IPO. This is a middle-tier performance for all major underwriters during the period.
As to valuation, RLX seeks a significant valuation premium over U.S. comparable Turning Point Brands ([TPB]).
In its favor, though, is RLX’ strong topline revenue growth rate and leading position in a huge market.
The main risk to the company’s business is the potential for negative government regulation, since the Chinese government is itself in a competitive position, selling legacy cigarettes to consumers.
However, I view this threat as only moderate, as the government also seeks to reduce the health care costs associated with legacy cigarette consumption.
Like many Chinese firms seeking to tap U.S. markets, the firm operates within a VIE structure or Variable Interest Entity. U.S. investors would only have an interest in an offshore firm with contractual rights to the firm’s operational results but would not own the underlying assets.
This is a legal gray area that brings the risk of management changing the terms of the contractual agreement or the Chinese government altering the legality of such arrangements. Prospective investors in the IPO would need to factor in this important structural uncertainty.
While there are regulatory risks the company faces and the IPO isn’t cheap, the firm’s growth potential, breakeven financial result and strong free cash flow generation mean the IPO is worth a close look.
Expected IPO Pricing Date: January 20, 2021.
1 me gusta
Es una pena que el resto del mundo no presione a China para que liberalice su mercado del tabaco. Si PM, BATS, IMB y JT puedesen operar en China …
6 Me gusta
